Global Biologics Market 2018-2024: By Application, Types, Segment, Opportunity, Industry Demand Analysis and Geography
Aug 6, 2018
New Report On Global Biologics Market: Drivers, Opportunities, Trends, and Forecasts 2018-2024 added to Orbisresearch.com store which has 121 pages.
Dallas, United States - August 6, 2018 /MarketersMedia/ —
Global Biologics Market – Drivers, Opportunities, Trends, and Forecasts: 2018–2024.
Overview: Biologics drugs are complex molecules that are manufactured from living organisms or components of living organisms. Biologics include a wide variety of products derived from human, animal, or microorganisms by using biotechnological processes. Many biologics are produced using recombinant DNA technology. They are sometimes referred to as biopharmaceuticals or biological drugs. Various types of biologic drugs include monoclonal antibody, recombinant proteins/hormones, vaccines, cell and gene therapy and others. These biologics may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system. Biologics are sometimes referred as referred to as biologic response modifiers, as they change the manner of operation of natural biologic intracellular and cellular actions.
Request a Sample Brochure! Get PDF Sample Copy@ http://www.orbisresearch.com/contacts/request-sample/2256097
The market for biologics is driven by increasing incidence of disease across the globe, increasing number of biologics approvals and emergence of next generation biologics such as cell and gene therapy. Strong pipelined products and huge number of ongoing clinical trials are providing market growth oppurtunity. Challenges associated with biologics production, high cost of the drug, increasing number of biologics going off patent and emergence of biosimilars are hampering market growth.
Market Analysis: The “Global Biologics market” is estimated to witness a CAGR of 9.9% during the forecast period 2018–2024. The global market is analyzed based on three segments – Product, Application and regions.
Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global biologics market, followed by Europe. North America dominates the biologics market due to increasing product approvals, increasing demand for the product to treat various disease conditions, and presence of established players in this region. Asia-Pacific region is expected to have the fastest growth rate during the forecasted period due to increasing research activities, flexible regulatory environment for clinical trials, growing awareness about biopharmaceutical therapeutics, and rising healthcare expenditure.
Product Analysis: The market by product is segmented into monoclonal antibodies, recombinant proteins/hormones, vaccines, cell and gene therapy and others. Monoclonal antibodies occupied major market share of global biologics market in 2017 and cell and gene therapy is expected to grow at high CAGR during the forecasted period. Wide application of monoclonal antibodies in treatment of various diseases makes this segment, a major shareholder of biologics products market.
Application Analysis: The market by application is segmented into cancer, infectious disease, immunological disorders, hematological disorders, cardiovascular disease and others. Among various application, cancer occupied the largest share in 2017 and is expected to grow at fastest rate during the forecasted period. Growing elderly population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.
Key Players: F. Hoffmann-La Roche, Amgen, Inc., Sanofi S.A., Novo Nordisk A/S, Johnson and Johnson, AbbVie, Inc., Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb, Merck & Co., Eli Lilly & Company Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company and other predominate and niche players.
Competitive Analysis: Currently cancer segment dominates the global biologics segment. Biologics are entering new therapeutic areas such as, asthma and allergy where they are not present historically. The key market players are taking the advantage of strategic deals and product approvals to increase their share in the market. For instance, in September 2017, GSK and AbCellera Biologics, Inc. entered an antibody discovery research collaboration, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. In August 2017, Novartis received first FDA approval from FDA for CAR-T cell therapy, Kymriah to treat patients with B-cell precursor acute lymphoblastic leukemia (ALL) and in May 2018, Novartis received second FDA approval for Kymriah to treat patients with B-cell lymphoma.
Benefits: The report provides complete details about the usage and adoption rate of biologics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
Companies Mentioned:
F. Hoffmann-La Roche, Amgen, Inc., Sanofi S.A., Novo Nordisk A/S, Johnson and Johnson, AbbVie, Inc., Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb, Merck & Co., Eli Lilly & Company Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company and other predominate and niche players
To make an enquiry on report@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2256097
Some Point from Table of Content:
1 Industry Outlook
1.1 Industry Overview
1.2 Industry Trends
1.2.1 R&D pipeline in pharmaceutical industry
1.2.2 Top pharma drugs by sales in 2017 ($Million)
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Biologics patent expiration in US and Europe (2010-2020)
3.3 Segmented Addressable Market (SAM)
3.4 Trends of the biologics market
3.5 Related Markets
3.5.1 Over the counter drugs
3.5.2 Orphan drugs
3.5.3 Human Insulin
4 Market Outlook
4.1 Market segmentation
4.2 PEST Analysis
4.3 Porter 5(Five) Forces
5 Market Characteristics
5.1 DRO – Global Biologics Market Dynamics
5.1.1 Drivers
5.1.1.1 Growing incidence of disease across the globe
5.1.1.2 Increasing number of biologics approvals
5.1.2 Opportunities
5.1.2.1 Strong portfolio of product pipeline and huge number of ongoing clinical trials
5.1.2.2 Increasing opportunities in emerging markets
5.1.3 Restraints
5.1.3.1 Challenges associated with biologics production 32
5.1.3.2 Increasing number of biologics going off patent and emergence of biosimilars
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Info:
Name: Hector Costello
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas,
Phone: +1 (214) 884-6817; +912064101019
For more information, please visit http://www.orbisresearch.com/reports/index/global-biologics-market-drivers-opportunities-trends-and-forecasts-2018-2024
Source: MarketersMedia
Release ID: 389374
More News
This Singaporean grandma, 73, couldn’t walk without pain. Today, she deadlifts 67.5kg
When 73-year-old Rosemina Hamzah stepped up to the hex bar at Singapore’s Mbold Seniors Hex Bar Deadlift Challenge in August, she was not just attempting her first deadlift competition – she was rewriting what ageing looks like. Latching onto 67.5kg (149lbs), more than her own body weight of 64kg, the novice lifter pulled it with ease – a personal best to win her category. It was a remarkable feat for a woman who, just over a year ago, could hardly walk and was constantly in pain. Before August...
From Runway to Boardroom: How Blacklane Makes Global Business Travel Seamless
Airport pickups, city-to-city transfers and chauffeurs by the hour: Blacklane’s service turns the journey into part of the working day The post From Runway to Boardroom: How Blacklane Makes Global Business Travel Seamless appeared first on Business Traveller.
Style Edit: Shiatzy Chen draws inspiration from orchids for SS27 at Paris Fashion Week
Florals don’t have to mean full bloom. For spring/summer 2027, Shiatzy Chen takes the orchid but looks beyond its purely decorative appeal to the proportions, movement and resilience of the plant. Presented at Paris Fashion Week on October 5, the new collection translates that botanical inspiration into a thoughtful line-up where fluidity and structure come together. The season forms part of the house’s year-long exploration of the Four Gentlemen of Eastern culture. Following on from the Resort...
Meet architect and designer Steve Leung, whose work spans from Hong Kong to Hokkaido
One of Hong Kong’s most prominent architects and interior designers, Steve Leung has been in the business for four decades and counting. In 1997, Leung restructured his architecture business and established two firms: Steve Leung Architects and Steve Leung Designers. Leung’s business has since grown to include brands like Steve Leung Hospitality, and he is now best known for both interior design and being an avid restaurateur. Ask any Hong Kong resident and they’ve probably, perhaps unknowingly,...
Canadian health reporter Helen Branswell dead at 69, remembered as 'pretty kickass' journalist
Helen Branswell, a journalist celebrated for her years of coverage on public health and infectious diseases, has died at the age of 69.
"It's Impossible To Communicate Just How Terrible It Is": People Are Sharing The Countries That Are Actually "Wildly Different" From How The Media Portrays Them
"I'm an American from Texas, and I think this place shocked me the most." View Entire Post ›
London wine club’s Shanghai outpost to offer Chinese drinkers a ‘sweet spot’
London-based private members’ wine club 67 Pall Mall is scheduled to open its first mainland China outpost in December, in Shanghai’s former French Concession. Founder Grant Ashton says the move reflects a global shift away from spirits – which can reach 40 per cent alcohol by volume (ABV) – towards wine, typically 12 to 14 per cent ABV. “Wine is halfway down to zero,” he says, mapping out the spectrum from spirits to non-alcoholic drinks. “If you’re starting from spirits, wine is your sweet...
"You Can Feel How Unwelcome You Are": 39 Cities People Recommend You Never, Ever, Ever Visit
"I want to run screaming out of there every time I have to visit my family that lives there. It’s claustrophobic, and I can’t wait to escape as soon as I arrive." View Entire Post ›
27 Products Reviewers Say They Can’t Believe They Ever Traveled Without
And I bet you're gonna say the same thing after trying them. View Entire Post ›
Outrigger Phi Phi Island Resort offers a tranquil escape with sustainability in mind
Considering the number of tourists who visit every year, there aren’t many luxury hotels on Thailand’s Phi Phi Islands, possibly the result of stringent measures put in place in recent years to prevent overtourism. Outrigger Phi Phi Island Resort is thus a welcome new addition to the scene. Located on the northern tip of Phi Phi Don Island, the main island in the Phi Phi archipelago, this laid-back, unpretentious resort sits on the quiet shores of Laem Tong Beach, within a protected national...
Pope Leo has cancerous growth removed in lung operation
Pope Leo XIV had a cancerous growth removed from his right lung in a 90-minute operation on Tuesday and "woke up normally" after the procedure, the Vatican said. A Vatican source said further tests were being carried out to determine if the cancer had spread. "To ensure the procedure was radical, the lower lobe of the right lung was removed," the Vatican said in a statement. FRANCE 24's Seema Gupta reports from Rome.
Touring Tuscany for Piero della Francesca’s Most Resplendent Artworks
A writer’s road trip in search of the early Renaissance master’s most resplendent works takes her to towns beyond Florence, the birthplace of the Italian Renaissance.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.